La Jolla im Auge behalten! - 500 Beiträge pro Seite

[yoppu]

Wenn heute die 4$ übersprungen werden, gehts ganz schnell up!
Auf die Watchlist nehmen!

[Bienenvater]

Hallo, - warum auf die Watchliste nehmen?
Analyse des Unternehmens und der Pipeline signalisieren: Kaufen! Ich denke, dieses Scheinchen wird noch Freude bereiten .

[Bienenvater]

....hmmmmm, offenbar glaubt mir das kein Schwein. ...na gut, - hol ich mir eben ein Bier....

[realox]

Hallo!
Neuigkeiten:

SAN DIEGO, Nov. 17 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today presented analyses showing statistically significant associations between changes from baseline in levels of antibodies to double-stranded DNA (dsDNA) and the relative risk of renal flare in both the Phase 2/3 and Phase 3 clinical trials of Riquent(TM). These results, in studies of approximately 500 patients, were presented at the American Society of Nephrology Annual Meeting being held November 14-17, 2003 in San Diego, CA.
Analyses of data using Cox``s Proportional Hazards Regression Model predict that a 50% reduction in antibodies to dsDNA from baseline is associated with a 52% lower risk of renal flare in the Phase 2/3 trial (p=0.0007) and a 53% lower risk in the Phase 3 trial (p<0.0001). These findings are consistent with previously released data showing that patients with sustained reductions in antibodies to dsDNA had fewer renal flares. These results will be submitted as part of the Company``s planned regulatory filings regarding Riquent.
Summary of four poster presentations at the American Society of Nephrology:
James Tumlin, M.D., Associate Professor of Medicine, Emory University School of Medicine, presented a poster entitled, "Efficacy Results from a Randomized Controlled Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients with a History of Renal Disease." The poster summarized data from the Phase 3 trial of Riquent in which 298 lupus patients with high affinity antibodies to Riquent at baseline were treated with Riquent or a placebo for up to 22 months.
Dr. Tumlin also presented a poster entitled, "Renal Flare in SLE Patients with Impaired Renal Function in a Randomized Controlled Trial of LJP 394." This poster summarized data from a subpopulation of patients in the Phase 3 and Phase 2/3 trials with impaired renal function.
Matthew Linnik, Ph.D., Chief Scientific Officer and Executive Vice President of Research at La Jolla Pharmaceutical, presented a poster entitled, "Reductions in Anti-dsDNA Antibodies and Reduced Risk of SLE Renal Flare and Major SLE Flare." This poster presented Cox regression analyses and sustained reduction analyses on data from the Phase 2/3 and Phase 3 trials.
Daniel Wallace, M.D., F.A.C.P., F.A.C.R., Clinical Chief of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, and Clinical Professor, UCLA School of Medicine, presented an abstract entitled, "Safety Results from a Randomized Controlled Trial of LJP 394 in SLE Patients with a History of Renal Disease." The abstract summarized safety data from the Phase 3 trial of Riquent that showed that Riquent was well tolerated for the duration of the trial in which patients were treated for periods of up to 22 months.
La Jolla Pharmaceutical Company is a biotechnology company developing therapeutics for antibody-mediated autoimmune diseases afflicting several million people in the United States and Europe. The Company is developing Riquent(TM), formerly known as LJP 394, for the treatment of lupus kidney disease, a leading cause of sickness and death in patients with lupus. The Company is also developing LJP 1082 for the treatment of antibody-mediated thrombosis, a condition in which patients suffer from recurrent stroke, deep-vein thrombosis and other thrombotic events. The Company``s common stock is traded on The Nasdaq Stock Market under the symbol LJPC. For more information about the Company, visit its Web site: http://www.ljpc.com/ .
Except for historical statements, this press release contains, and the presentations referred to above contained, forward-looking statements involving significant risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results to differ materially from our current expectations. Forward-looking statements include those which express a plan, belief, expectation, estimation, anticipation, intent, contingency, future development or similar expression. Although we plan to submit a New Drug Application ("NDA") for Riquent(TM), there is no guarantee that regulatory authorities will approve Riquent in a timely manner, or at all. Our analyses of clinical results of Riquent, previously known as LJP 394, our drug candidate for the treatment of systemic lupus erythematosus ("lupus"), and LJP 1082, our drug candidate for the treatment of antibody-mediated thrombosis ("thrombosis"), are ongoing and could result in a finding that these drug candidates are not effective in large patient populations, do not provide a meaningful clinical benefit, or may reveal a potential safety issue requiring us to develop new candidates. The analysis of the data from our Phase 3 trial of Riquent has shown that the trial did not reach statistical significance with respect to its primary endpoint, time to renal flare. Although we plan to submit an NDA for Riquent, the results from our clinical trials of Riquent may not ultimately be sufficient to obtain regulatory clearance to market Riquent either in the U.S. or Europe, and we may be required to conduct additional clinical studies to demonstrate the safety and efficacy of Riquent in order to obtain marketing approval. There is no guarantee, however, that we will have the necessary resources to complete any additional trial, that we will elect to conduct an additional trial, or that any additional trial will sufficiently demonstrate the safety and efficacy of Riquent. Our blood test to measure the binding affinity for Riquent is experimental, has not been validated by independent laboratories, may require regulatory approval, and will likely be necessary for the approval and the commercialization of Riquent. Our other potential drug candidates are at earlier stages of development and involve comparable risks. Analysis of our clinical trials could have negative or inconclusive results. Any positive results observed to date may not be indicative of future results. In any event, regulatory authorities may require additional clinical trials, or may not approve our drugs. Our ability to develop and sell our products in the future may be affected by the intellectual property rights of third parties. Additional risk factors include the uncertainty and timing of: obtaining required regulatory approvals, including delays associated with any approvals that we may obtain; the clear need for additional financing; FDA approval of our manufacturing facilities and processes; the increase in capacity of our manufacturing capabilities for possible commercialization; successfully marketing and selling our products; our lack of manufacturing, marketing, and sales experience; generating future revenue from product sales or other sources such as collaborative relationships; future profitability; and our dependence on patents and other proprietary rights. Readers are cautioned to not place undue reliance upon forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date hereof. Interested parties are urged to review the risks described in our Annual Report on Form 10-K for the year ended December 31, 2002, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time.
La Jolla Pharmaceutical Company
© PR Newswire


r.

[mcrotznase]

vorbörslich 7,4 % oder 0,23 cent/us

[realox]

sieht doch eigentlich ganz gut aus?!

[mcrotznase]

vorbörslich 8,7 % aufgrund gravierenden Neuigkeiten!

[realox]

ich liebe es wenn ein plan funktioniert!

[realox]

NEWS:

SAN DIEGO, Dec. 16 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company today announced that it has submitted a New Drug Application with the United States Food and Drug Administration for Riquent(TM), its drug candidate for the treatment of patients with lupus (systemic lupus erythematosus or SLE) at risk of renal disease. Riquent is designed to reduce the levels of antibodies to double-stranded DNA (dsDNA), which are believed to be responsible for lupus renal disease, a primary cause of sickness and death in lupus patients. Riquent has received orphan drug status in the United States and Europe.
"Our New Drug Application for Riquent is supported by data from two of the longest and largest randomized clinical studies ever conducted to evaluate a drug candidate in lupus patients," said Steve Engle, Chairman and CEO of La Jolla Pharmaceutical Company. "We believe these studies show that patients treated with Riquent experienced reductions in the levels of antibodies to dsDNA and that reductions in these antibodies were associated with fewer renal flares. These results were seen even though many patients were on immunosuppressive drug therapies."
Engle added, "This submission represents an important milestone for the Company and a potentially significant advance for lupus patients in combating their disease."
New Drug Application
The evidence supporting the safety and effectiveness of Riquent is derived from 12 clinical trials involving approximately 900 patients and subjects conducted over a period of approximately 10 years. The submission is primarily based on previously announced data from the Company``s Phase 3 trial of Riquent that enrolled 298 patients with high-affinity antibodies to Riquent who were treated for up to 22 months and its Phase 2/3 trial that enrolled 189 high-affinity patients who were treated for up to 18 months. The trials focused on the leading causes of sickness and death in lupus patients: renal flares and treatments with immunosuppressive drugs.
About Lupus and Riquent
Lupus is a chronic, life-threatening autoimmune disease afflicting approximately one million people in the United States and Europe. About 90% of lupus patients are female. Most patients develop the disease during their childbearing years. Approximately 50% of lupus patients have renal disease. Renal disease is one of the most serious aspects of lupus and can lead to irreversible kidney damage, kidney failure and the need for dialysis. Antibodies to dsDNA can be detected in most lupus patients and are considered diagnostic for the disease.
The current standard of care for lupus renal disease often involves treatment with high doses of corticosteroids and immunosuppressive drugs that can cause severe side effects including diabetes, hypertension and sterility, and may leave patients vulnerable to opportunistic infections. The morbidity resulting from current treatments can be worse than the disease itself.
Riquent is designed to be highly specific and not to suppress the normal healthy functions of the immune system. Riquent appeared to be well tolerated in all studies with no apparent differences in the overall incidence of serious adverse events or adverse events between Riquent-treated and placebo-treated patients.
La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biotechnology company developing therapeutics for antibody-mediated autoimmune diseases and inflammation afflicting several million people in the United States and Europe. The Company is developing Riquent(TM), formerly known as LJP 394, for the treatment of lupus renal disease, a leading cause of sickness and death in patients with lupus. The Company is also developing LJP 1082 for the treatment of antibody-mediated thrombosis, a condition in which patients suffer from recurrent stroke, deep-vein thrombosis and other thrombotic events. The Company``s common stock is traded on The Nasdaq Stock Market under the symbol LJPC. For more information about the Company, visit its Web site: http://www.ljpc.com/ .
Except for historical statements, this press release contains forward-looking statements involving significant risks and uncertainties, and a number of factors, both foreseen and unforeseen, could cause actual results to differ materially from our current expectations. Forward-looking statements include those that express a plan, belief, expectation, estimation, anticipation, intent, contingency, future development or similar expression. Although we have submitted a New Drug Application ("NDA") for Riquent(TM) with the United States Food and Drug Administration (the "FDA"), there is no guarantee that it will accept the NDA submission or approve Riquent in a timely manner, or at all. Our analyses of clinical results of Riquent, previously known as LJP 394, our drug candidate for the treatment of systemic lupus erythematosus ("lupus"), and LJP 1082, our drug candidate for the treatment of antibody-mediated thrombosis ("thrombosis"), are ongoing and could result in a finding that these drug candidates are not effective in large patient populations, do not provide a meaningful clinical benefit, or may reveal a potential safety issue requiring us to develop new candidates. The analysis of the data from our Phase 3 trial of Riquent has shown that the trial did not reach statistical significance with respect to its primary endpoint, time to renal flare. Although we have submitted an NDA for Riquent with the FDA, the results from our clinical trials of Riquent may not ultimately be sufficient to obtain regulatory clearance to market Riquent either in the U.S. or Europe, and we may be required to conduct additional clinical studies to demonstrate the safety and efficacy of Riquent in order to obtain marketing approval. There is no guarantee, however, that we will have the necessary resources to complete any additional trial, that we will elect to conduct an additional trial, or that any additional trial will sufficiently demonstrate the safety and efficacy of Riquent. Our blood test to measure the binding affinity for Riquent is experimental, has not been validated by independent laboratories, may require regulatory approval, and will likely be necessary for the approval and the commercialization of Riquent. Our other potential drug candidates are at earlier stages of development and involve comparable risks. Analysis of our clinical trials could have negative or inconclusive results. Any positive results observed to date may not be indicative of future results. In any event, regulatory authorities may require additional clinical trials, or may not approve our drugs. Our ability to develop and sell our products in the future may be affected by the intellectual property rights of third parties. Additional risk factors include the uncertainty and timing of: obtaining required regulatory approvals, including delays associated with any approvals that we may obtain; the clear need for additional financing; FDA approval of our manufacturing facilities and processes; the increase in capacity of our manufacturing capabilities for possible commercialization; successfully marketing and selling our products; our lack of manufacturing, marketing, and sales experience; generating future revenue from product sales or other sources such as collaborative relationships; future profitability; and our dependence on patents and other proprietary rights. Readers are cautioned to not place undue reliance upon forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after the date hereof. Interested parties are urged to review the risks described in our Annual Report on Form 10-K for the year ended December 31, 2002, and in other reports and registration statements that we file with the Securities and Exchange Commission from time to time.
La Jolla Pharmaceutical Company
© PR Newswire

[Bienenvater]

...hmm...jetzt hängt also alles an diesem Lupus. Wenn das Zeug zugelassen wird, geht die Aktie ab wie Nachbars Lupo. Wenn nicht, - ist die Firma möglicherweise bald bankrott.

[kalock]

Gestern beachtlicher US-Börsenumsatz bei stabilem Kurs

[mcrotznase]

gestern 8 % in USA. gehen aufgrund der zulassung (evtl.)
ja ganz gut. welche ziele kann man erwarten?

[goreng]

was gibts neues???
Danke für Infos, schnelle Antwort wäre schön, ahne da etwas!

[Bienenvater]

...hm....siehe posting 3: habe mir gerade wieder ein bier geholt...

[Der Engel]

17.02. 14:16
La Jolla Pharma: Kursplus nach FDA-OK

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Die Aktien von La Jolla Pharmaceuticals steigen aktuell um 6.5% auf $4.15, nachdem das Unternehmen von der US-Gesundheitsbehörde FDA eine Vermarktungszulassung für das Lupus-Medikament Riquent erhalten hatte. Riquent sei das erste Medikament seit 30 Jahren, dass die Krankheit behandelbar mache, betont das Pharma-Unternehmen.



aber warum ist sie dann heute gefallen??????????

[Isabartels]

Jetzt einsteigen oder kommt da noch was was wir nicht wissen??

[highlander101]

Hi
ich habe mir heute La Jolla gekauft, da ich die nachricht erhalten habe, daß das Lupus-Medikament von der FDA ihre Zulassung bekommen hat. Hier die tolle News:

17.02. 14:16
La Jolla Pharma: Kursplus nach FDA-OK
(©BörseGo - http://www.boerse-go.de)
Die Aktien von La Jolla Pharmaceuticals steigen aktuell um 6.5% auf $4.15, nachdem das Unternehmen von der US-Gesundheitsbehörde FDA eine Vermarktungszulassung für das Lupus-Medikament Riquent erhalten hatte. Riquent sei das erste Medikament seit 30 Jahren, dass die Krankheit behandelbar mache, betont das Pharma-Unternehmen.

Leider ist der Kurs gestern wieder eingebrochen, denke aber das dies schon demnächst korrigiert wird und dann die chance besteht, daß der Wert auf 4-6 € steigt. Es ist ja genial, daß ein biotechunternehmen die Zulassung für ihr Produkt erhalten hat. Dadurch sind steigende Einnahmen und Gewinne erreichbar.
Der Aktionär hatte am 16.01. bereits auf die große Chance bei einer Zulassung gesprochen, aber natürlich auch auf die Risiken, wenn die FDA negativ entschieden hätte. Zum Glück ist dies nicht der Fall. Ich habe mich mal heute mit diesem Wert eingedeckt.

[Isabartels]

Du bist aber ein ganz schneller.
Schau mal Posting #15

[Isabartels]

Ist aber schon komisch, dass das Teil jetzt schon den 2.tag in Folge fällt.

[fiddi9]

gestern Abend, Nasdaq ist sie auch wieder gefallen.

Last 3.50 Open 3.69
Change -0.06 Previous Close 3.56
% Change -1.69%

Volume 810,846
Avg Daily Volume 601,600

schon komisch. Oder ist es Sell on good News.

MFG

[fiddi9]

mmmh und heute fallen die schon wieder.

Ich bin aber noch nicht nervös
KK war 2.85

MFG

[gontard]

52 wochen tief 1,12 also gewinnmitnahmen

[fiddi9]

La Jolla Pharmaceutical Company Announces Common Stock Offering
February 20, 2004 07:30:00 AM ET


SAN DIEGO, Feb. 20 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company announced today that it has agreed to sell 8,695,653 shares of its common stock in an underwritten public offering. Pursuant to the terms of the underwriting agreement, the shares will be offered to the public at a price per share of $3.15. The Company also granted the underwriter a 30-day option to purchase an additional 1,304,347 shares to cover over-allotments. All of the shares are being offered by the Company.

Pacific Growth Equities, LLC is acting as underwriter for the offering. A copy of the prospectus and accompanying prospectus supplement relating to the offering can be obtained from Pacific Growth Equities, LLC at One Bush Street, San Francisco, CA 94104. The offering was made pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission.

La Jolla Pharmaceutical Company is a biotechnology company developing therapeutics for antibody-mediated autoimmune diseases including lupus and antibody-mediated thrombosis.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from current expectations. The prospectus and prospectus supplement contain important information, and potential investors are urged to read these documents and other relevant documents filed with the Securities and Exchange Commission.

© 2004 PRNewswire

[Puck1]

An fiidi9

...und was heißt das im Einzelnen?

[fiddi9]

weiss auch nicht genau. Die verkaufen eigene Aktien? mmmh

vielleicht finded sich ja jemend der es hier besser weiss,

aber heute steigt sie wieder bisschen an de Nasdaq.

Im Moment $3,28

[Isabartels]

--------------------------------------------------------------------------------

20.02. 13:51
La Jolla Pharma nach Kapitalerhöhung im Minus

--------------------------------------------------------------------------------
(©BörseGo - http://www.boerse-go.de)
Der US-Medikamentenhersteller La Jolla Pharmaceuticals wird 8.7 Millionen Aktien zu einem Kurs je Aktie von $3.15 platzieren. Zudem gebe es eine Greenshoe-Option mit weiteren 1.3 Millionen Aktien, so das US-Biotech-Unternehmen am Freitag in einer Pressemitteilung. Die Aktie verliert vorbörslich um 0.3% auf 3.25 Dollar.

[fiddi9]

Danke Isabartels

[Isabartels]

gern geschehen, fiddi!

[Joe_Trader]

Hallo Aktie ist sehr interessant.
Weiß jemand schon wann die Aktien ausgegeben werden ,falls ihr sie ja habt werdet ihr ja Bescheid bekommen.
Oder wird sie nur an Institute ausgegeben und nicht an Privatanleger.
joe

[Joe_Trader]

Bin gerade Eingestiegen,vorbörslich in den USA im Plus bei
3,29 Dollar.
Mal schauen.
joe

[Joe_Trader]

Zuletzt geprügelt, nun vor Zulassung?

(22.12.2003)

Bei 4,20 Euro hatten wir am 28. September diesen von „Global Biotech Investing“ besprochenen Wert vorgestellt. Damals empfahlen wir abzuwarten, ob der Kurs konsolidiert. Wegen zunächst enttäuschender Daten brach dieser dann prompt ein. Und nun wurde vergangene Woche just bei der FDA ein Zulassungsantrag für das Lupus-Medikament Riquent gestellt! In den letzten Monaten wurden nämlich weitere Studien durchgeführt, die zwar keine vollständige Heilung erbrachten, aber dennoch eine deutliche Linderung der Krankheit. Insgesamt ist das Präparat wesentlich besser als auf dem Markt befindliche Medikamente. Sicherheitsbedenken bestehen hingegen nicht. Die 2,64 Euro Kurs von heute dürften damit in Kürze vorüber sein. Während auch wir Zweifel am Kursziel der Analysten von „Fulcrum“ haben, die 14 US-Dollar veranschlagen, sollte das Potenzial groß sein. Mit Vorsicht ist eines zu behandeln: Die Cashreserven von La Jolla werden voraussichtlich nur noch bis Ende 2004 reichen, womit die Zukunft des Unternehmens von der Zulassung Riquents abhängig sein dürfte.

[Joe_Trader]

Vorbörslich 3,32 US Dollar
joe

[Joe_Trader]

In den USA wurden ab Freitag bis Heute den 23.2.2004
9 Börsenbriefe geschrieben für La Jolla,natürlich gegen Cash.
Steht jetzt 3,33 US Dollar im Plus.
Ob das was verspricht???????????
joe

[Joe_Trader]

Nach dem nicht so schlechten Start in den USA wurde der Ask in Deutschland gleich angehoben.
Hoffentlich ist das nicht von allzu kurzer Dauer.
joe

[fiddi9]

na ja der Kurs geht schon wieder zurück in den USA.

[gontard]

die schmeisen das teil ohne ende die fack amis

[fiddi9]

das sind hosenschisser

[Joe_Trader]

Mitte Oktober wird mit der Vermarktung gerechnet,wenn ich das richtig Verstanden habe.
2 Strong Buy empfehlungen aus den USA.Langfristig.
Long-Term Sentiment: Strong Buy 02/23/04 07:09 pm
Msg: 20732 of 20732

From Bioworld Today, Monday February 23, 2004

La Jolla Raises $27M Following FDA Acceptance of Riquent NDA

Just three days after the FDA accepted the Riquent new drug application for review, La Jolla Pharmaceutical Co. conducted a public offering to raise about $27.4 million.
Pacific Growth Equities LLC, of San Francisco, is serving as underwriter for the offering. It has a 30-day option to
purchase 1.3 million more shares to cover overallotments. The San Diego-based company sold almost 8.7 million shares at $3.15 each - a small discount to La Jolla`s recent
closing stock prices. The stock rose 1 cent Friday to close at $3.27.
The company submitted the NDA for Riquent in December as a treatment for lupus patients at risk of renal disease. The product is designed to reduce the levels of antibodies to double stranded DNA believed to be responsible for lupus renal disease, which often causes sickness and death.
Riquent has orphan drug designation in the U.S. and Europe. Last week, La Jolla announced that the FDA accepted the NDA
for review. Steven Engle, chairman and CEO of La Jolla, said the company waited for the acceptance before going forward with Friday`s
offering. "We`re a biotech company and we want to make sure we have funds to take us through the review process", Engle
told Bioworld Today.
Riquent missed its primary endpoint in two Phase III trials, but it showed positive trends, prompting the company to begin filing an NDA last may following discussions with the
FDA. Phase III data from a year ago showed Riquent did not demonstrate a statistically significant increase in time to renal flare. The news caused the company`s stock to drop
72.5 percent. However, the trial did show positive trends in the intent-to-treat population. There were fewer renal
flares and major systemic lupus erythematosus flares in Riquent-treated patients compared to placebo-treated patients.
With the FDA accepting the NDA for review, the company could get a decision this year on whether it can market the drug.
"We think that we`re currently on the standard 10-month [Prescription Drug User Fee Act] process," Engle said. Best case scenario, the company could gain approval as early as October and Riquent could be launched in 2005, Engle said. "There are no guarantees," Engle said, "but at least
it appears that all of the data required are in the NDA filing and the process can move forward".
The company restricted its comments due to SEC-imposed quiet-period rules, but Gail Sloan, the company`s senior director of finance and controller, said the company
intended to use proceeds to fund research and development of potential products, to expand and validate existing facilities and processes and infrastructures, and for other
general corporate purposes. The company`s last public offering was conducted in August, when it raised $22.4 million.
Following the offering, La Jolla will have 59.8 million outstanding shares. For 2003`s third quarter, the company reported a $6.9 million net loss - 15 cents per share. At
that time, it had cash, cash equivalents and short-term investments of $39.3 million, which included proceeds from the August public offering. Assuming it would have no
significant clinical trials or commercialization costs, the company has enough money to cover its expenses through the
beginning of the fourth quarter of this year, Engle said.
The company`s Toleragen drug candidates are designed to inactivate targeted B cells, stopping them from producing disease-causing antibodies. In addition to Riquent, the
company is studying LJP 1082 in a Phase I/II trial for antibody-mediated thrombosis. Data released last October showed that circulating antibodies from treated patients bound to LJP 1082 in a dose-dependent manner.


Noch eine Nachricht.
Long-Term Sentiment: Strong Buy 02/23/04 07:01 pm
Msg: 20731 of 20732

BioCentury Part II Vol. 12, No. 9 February 23, 2004

REGULATORY:
La Jolla Pharmaceutical Corp. (LJPC), San Diego, Calif.
Product: Riquent (LJP 394) ds-oligonucleotides
Business: Autoimmune
LJPC said FDA accepted for review its NDA for Riquent to treat lupus patients at risk of developing renal disease. Riquent (LJP 394) is composed of ds-oligonucleotides that
bind to double-stranded DNA (dsDNA) antibodies on B cells.
Phase III data presented in February 2003 showed Riquent did not significantly decrease time to renal flare, the primary endpoint. Riquent has Orphan Drug designation in the U.S. and Europe. LJPC said the PDUFA date is in mid-October.


Meine Meinung wird schon werden.
Kann jemand wohl übersetzen?
joe

[Joe_Trader]

weiß jemand wann die neuen Aktien auf den Markt gebracht werden???
Weiß jemand wieviel Umsatz das Medikament bringt???
joe

[fiddi9]

zahlen hab ich keine aber der Kurs wird erst richtig anspringen wenn die Zulassung da ist. Im Oktober vielleicht.

MFG
fiddi

Geduld muss man schon haben

[Joe_Trader]

Vorbörslich steht der ASK in den USA auf 3,45 USD BID 3,01 USD.Kommt eine Technische Gegenreaktion ????
1, 00 USD in einer Kursverlust schreien danach.
Wäre auch günstig Kurzfristig aufzusteigen,oder ???
joe

[Joe_Trader]

Wenn ich es richtig übersetzt habe ist die Neuausgabe beendet.
Gestern kam noch eine Outperform für LJPC raus ,für die 1-4 kommenden Wochen.

Market Pulse Announces Its Investment Opinion for Wednesday, February 25, 2004: PLRS, FLWE, LJPC, ABGX
ATLANTA, GA -- (MARKET WIRE) -- 25-02-2004 -- Market Pulse is pleased to introduce our featured stock, Pluristem Life Systems, Inc. (OTC BB: PLRS) to the investment community! Pluristem is new to Market Pulse and is aiming to become a leader in stem cell expansion! Pluristem has had some excellent news announcements out lately! Watch this stock move! Other notable stocks that look great lately from a fundamental and technical perspective include:

Fellows Energy Ltd. (OTC BB: FLWE): Bullish

LaJolla Pharmaceutical Co. (NASDAQ: LJPC): Market Outperform

Recommendation Meanings

These recommendations are investment opinions of Market-Pulse.com and reflect the stock`s potential to move over the next one to four weeks of trading. This analysis is done from a technical and fundamental perspective.

joe

[Joe_Trader]

Yo Offering ist komplett!!!!!
Heute geht es wohl wieder Aufwärts,hoffw ich.


+DJ La Jolla Pharmaceutical Co Completes Stk Offering>LJPC

02/26/2004
Dow Jones News Services
(Copyright © 2004 Dow Jones & Company, Inc.)



(MORE) Dow Jones Newswires

02-26-04 0746ET

*DJ La Jolla Pharm Sees $25.6M Proceeds From 8.7M-Shr Offer



(MORE) Dow Jones Newswires

02-26-04 0747ET


Joe

[fiddi9]

ja das hoffe ich auch Joe.

Bin schon dabei

MFG

[fiddi9]

$3,11 im moment

[Joe_Trader]

Scheien nicht viele investiert zu sein.
Meiner Meinung nach werden wir bald über 3,15 US Dollar stehen.
Denke werden auch hier Kurse von 3,20 € sehen ,vielleicht schon nächste Woche.
joe

[fiddi9]

@Joe,

es würde mich aber freuen wenn du immer etwas posten würdest wenn es etwas neues bigt. Danke.


MFG
fiddi

[fiddi9]

$ 3,16

[Joe_Trader]

Hat jemand mal gelesen wieviel das zugelassene Mittel einspielen kann oder wird ???????
Habe im amerikanischen Board was gehört,aber ob man dem Glauben schenken darf ist zubezweifeln.
Man würde 1000 US Dollar pro Patient verdienen.
Ihr könnt das mal hochrechnen,ich glaube meine Bedenken sind gerechtfertigt.
joe

[zitterbacke1]

ein paar meinungen sollte die zulassung erfolgen

7,5
fortis sagt 10
und einige denken 14

wir werden sehen.

[Joe_Trader]

In der letzten Stunde hohe Umsätze in den USA.
Kommt da was????????????????????????!!!!!!!!!!!!!!!!!!!!!!!
joe

[gontard]

german euro

[Joe_Trader]

was meinst du??????????????

[Joe_Trader]

COMBINED REAL-TIME ORDER BOOK
Bid Orders
Price Order Size Institution
3.18 100 Archipelago
3.18 3000 INET
3.16 5000 INET
3.15 5575 INET
3.14 2000 Archipelago
3.10 7600 Archipelago
3.10 9810 INET
3.09 1600 INET
3.08 250 INET
3.02 300 INET
3.01 100 Archipelago
3.00 4100 Archipelago
3.00 494 INET

Ask Orders
Price Order Size Institution
3.20 600 Archipelago
3.20 700 INET
3.22 400 INET
3.23 4932 INET
3.24 200 Archipelago
3.25 1000 INET
3.27 504 INET
3.28 300 INET
3.29 500 Archipelago
3.30 4100 Archipelago
3.30 900 INET
3.38 100 Archipelago

[fiddi9]

$3.20

[Joe_Trader]

ja sieht gut aus.